These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25896426)

  • 21. Identification of di-(2-ethylhexyl) phthalate-induced carboxylesterase 1 in C57BL/6 mouse liver microsomes: purification, cDNA cloning, and baculovirus-mediated expression.
    Furihata T; Hosokawa M; Koyano N; Nakamura T; Satoh T; Chiba K
    Drug Metab Dispos; 2004 Oct; 32(10):1170-7. PubMed ID: 15269189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is genetic variability in carboxylesterase-1 and carboxylesterase-2 drug metabolism an important component of personalized medicine?
    Laizure SC; Parker RB
    Xenobiotica; 2020 Jan; 50(1):92-100. PubMed ID: 31601149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics.
    Mussap M; Loddo C; Fanni C; Fanos V
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):115-134. PubMed ID: 31958027
    [No Abstract]   [Full Text] [Related]  

  • 24. The mammalian carboxylesterases: from molecules to functions.
    Satoh T; Hosokawa M
    Annu Rev Pharmacol Toxicol; 1998; 38():257-88. PubMed ID: 9597156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural Products as Modulators of CES1 Activity.
    Qian Y; Markowitz JS
    Drug Metab Dispos; 2020 Oct; 48(10):993-1007. PubMed ID: 32591414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboxylesterase 1 (Ces1): from monocyte marker to major player.
    Markey GM
    J Clin Pathol; 2011 Feb; 64(2):107-9. PubMed ID: 21177752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbonate-Based Fluorescent Chemical Tool for Uncovering Carboxylesterase 1 (CES1) Activity Variations in Live Cells.
    Singh A; Gao M; Karns CJ; Spidle TP; Beck MW
    Chembiochem; 2022 Jun; 23(12):e202200069. PubMed ID: 35255177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human.
    Williams ET; Bacon JA; Bender DM; Lowinger JJ; Guo WK; Ehsani ME; Wang X; Wang H; Qian YW; Ruterbories KJ; Wrighton SA; Perkins EJ
    Drug Metab Dispos; 2011 Dec; 39(12):2305-13. PubMed ID: 21918037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of individuality in drug metabolism by high-throughput metabolomics: The fast line for personalized medicine.
    Trifonova O; Knight RA; Lisitsa A; Melino G; Antonov AV
    Drug Discov Today; 2016 Jan; 21(1):103-110. PubMed ID: 26220091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic carboxylesterase 1 is induced by glucose and regulates postprandial glucose levels.
    Xu J; Yin L; Xu Y; Li Y; Zalzala M; Cheng G; Zhang Y
    PLoS One; 2014; 9(10):e109663. PubMed ID: 25285996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Research on pharmacometabolomics].
    Zhang ZX; Gao XY
    Zhongguo Zhong Yao Za Zhi; 2018 Mar; 43(6):1093-1098. PubMed ID: 29676113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism.
    Shi J; Xiao J; Wang X; Jung SM; Bleske BE; Markowitz JS; Patrick KS; Zhu HJ
    Clin Pharmacol Ther; 2022 Apr; 111(4):878-885. PubMed ID: 34743324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous absolute protein quantification of carboxylesterases 1 and 2 in human liver tissue fractions using liquid chromatography-tandem mass spectrometry.
    Sato Y; Miyashita A; Iwatsubo T; Usui T
    Drug Metab Dispos; 2012 Jul; 40(7):1389-96. PubMed ID: 22504157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of regulatory variants of carboxylesterase 1 (CES1): A proof-of-concept study for the application of the Allele-Specific Protein Expression (ASPE) assay in identifying cis-acting regulatory genetic polymorphisms.
    Her L; Shi J; Wang X; He B; Smith LS; Jiang H; Zhu HJ
    Proteomics; 2023 Jan; 23(1):e2200176. PubMed ID: 36413357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants.
    Zhu HJ; Brinda B; Froehlich TE; Markowitz JS
    Pharmacogenet Genomics; 2012 Mar; 22(3):215-8. PubMed ID: 22237548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carboxylesterase 1 genes: systematic review and evaluation of existing genotyping procedures.
    Rasmussen HB; Madsen MB;
    Drug Metab Pers Ther; 2018 Mar; 33(1):3-14. PubMed ID: 29427553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase.
    Shimizu M; Fukami T; Nakajima M; Yokoi T
    Drug Metab Dispos; 2014 Jul; 42(7):1103-9. PubMed ID: 24751575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacometabonomics: data processing and statistical analysis.
    Fu J; Zhang Y; Liu J; Lian X; Tang J; Zhu F
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33866355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia.
    Quiroga AD; Li L; Trötzmüller M; Nelson R; Proctor SD; Köfeler H; Lehner R
    Hepatology; 2012 Dec; 56(6):2188-98. PubMed ID: 22806626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver.
    Sato Y; Miyashita A; Iwatsubo T; Usui T
    Drug Metab Dispos; 2012 May; 40(5):902-6. PubMed ID: 22293119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.